Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03265080 · ClinicalTrials.gov registry record · Phase 1
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
A Phase 1 study, sponsored by Advaxis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03265080: Clinical Trial Phase 1 study, sponsored by Advaxis.
NCT03265080 is a Phase 1 study that was terminated before completion, run by Advaxis. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03265080, a Phase 1 study, was terminated before completion, sponsored by Advaxis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL ADXS-NEO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 1 |
Why NCT03265080 stopped before completion
NCT03265080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03265080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03265080 about?
NCT03265080 is a clinical study titled "A Study of ADXS-NEO Expressing Personalized Tumor Antigens". This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).
What is the current status of trial NCT03265080?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-03-28. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03265080?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), ADXS-NEO (BIOLOGICAL).
Who is sponsoring clinical trial NCT03265080?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03265080's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI